Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Apr 13;11 Suppl 3(Suppl 3):S30.
doi: 10.1186/1471-2458-11-S3-S30.

An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children

Harish Nair  1 , Vasundhara R Verma, Evropi Theodoratou, Lina Zgaga, Tanvir Huda, Eric A F Simões, Peter F Wright, Igor Rudan, Harry Campbell
Affiliations
Review

An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children

Harish Nair et al. BMC Public Health. .

Abstract

Background: Respiratory Syncytial Virus (RSV) is the leading cause of acute lower respiratory infections (ALRI) in children. It is estimated to cause approximately 33.8 million new episodes of ALRI in children annually, 96% of these occurring in developing countries. It is also estimated to result in about 53,000 to 199,000 deaths annually in young children. Currently there are several vaccine and immunoprophylaxis candidates against RSV in the developmental phase targeting active and passive immunization.

Methods: We used a modified CHNRI methodology for setting priorities in health research investments. This was done in two stages. In Stage I, we systematically reviewed the literature related to emerging vaccines against RSV relevant to 12 criteria of interest. In Stage II, we conducted an expert opinion exercise by inviting 20 experts (leading basic scientists, international public health researchers, international policy makers and representatives of pharmaceutical companies). The policy makers and industry representatives accepted our invitation on the condition of anonymity, due to the sensitive nature of their involvement in such exercises. They answered questions from the CHNRI framework and their "collective optimism" towards each criterion was documented on a scale from 0 to 100%.

Results: In the case of candidate vaccines for active immunization of infants against RSV, the experts expressed very low levels of optimism for low product cost, affordability and low cost of development; moderate levels of optimism regarding the criteria of answerability, likelihood of efficacy, deliverability, sustainability and acceptance to end users for the interventions; and high levels of optimism regarding impact on equity and acceptance to health workers. While considering the candidate vaccines targeting pregnant women, the panel expressed low levels of optimism for low product cost, affordability, answerability and low development cost; moderate levels of optimism for likelihood of efficacy, deliverability, sustainability and impact on equity; high levels of optimism regarding acceptance to end users and health workers. The group also evaluated immunoprophylaxis against RSV using monoclonal antibodies and expressed no optimism towards low product cost; very low levels of optimism regarding deliverability, affordability, sustainability, low implementation cost and impact on equity; moderate levels of optimism against the criteria of answerability, likelihood of efficacy, acceptance to end-users and health workers; and high levels of optimism regarding low development cost. They felt that either of these vaccines would have a high impact on reducing burden of childhood ALRI due to RSV and reduce the overall childhood ALRI burden by a maximum of about 10%.

Conclusion: Although monoclonal antibodies have proven to be effective in providing protection to high-risk infants, their introduction in resource poor settings might be limited by high cost associated with them. Candidate vaccines for active immunization of infants against RSV hold greatest promise. Introduction of a low cost vaccine against RSV would reduce the inequitable distribution of burden due to childhood ALRI and will most likely have a high impact on morbidity and mortality due to severe ALRI.

PubMed Disclaimer

Figures

Figure 1
Figure 1
A summary of Stage I of the CHNRI process of evaluation of an emerging intervention (a systematic review of the key CHNRI criteria). CHNRI- Child Health and Nutrition Research Initiative
Figure 2
Figure 2
A summary of Stage II of the CHNRI process of evaluation of an emerging intervention (an expert opinion exercise using the CHNRI criteria). CHNRI- Child Health and Nutrition Research Initiative
Figure 3
Figure 3
The current status of the research into RSV vaccines for active immunization. RSV- respiratory syncytial virus
Figure 4
Figure 4
The current status of the research into immunotherapy against RSV. RSV- respiratory syncytial virus
Figure 5
Figure 5
The results of Stage II of the CHNRI process – an expert opinion exercise assessing the potential usefulness of investment in vaccines for active immunization of infants against RSV. CHNRI- Child Health and Nutrition Research Initiative
Figure 6
Figure 6
The results of Stage II CHNRI process – an expert opinion exercise assessing the potential usefulness of investment in vaccines for immunization of pregnant women with vaccines against RSV. CHNRI- Child Health and Nutrition Research Initiative
Figure 7
Figure 7
The results of Stage II CHNRI process – an expert opinion exercise assessing the potential usefulness of investment in monoclonal antibodies for passive immunization of infants against RSV. CHNRI- Child Health and Nutrition Research Initiative
See this image and copyright information in PMC

References

    1. Nair H, Nokes D, Gessner B, Dherani M, Madhi S, Singleton R, O'Brien K, Roca A, Wright P, Bruce N, Chandran A, Theodoratou E, Sutanto A, Sedyaningsih E, Ngama M, Munywoki P, Kartasasmita C, Simoes E, Rudan I, Weber M, Campbell H. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375(9725):1545–1555. doi: 10.1016/S0140-6736(10)60206-1. - DOI - PMC - PubMed
    1. Stang PE. The Economic Burden of Respiratory Syncytial Virus-Associated Bronchiolitis Hospitalizations. Arch Pediatr Adolesc Med. 2001;155(1):95–96. - PubMed
    1. Wright PF, Cutts FT. Generic protocol to examine the incidence of lower respiratory infection due to respiratory syncytial virus in children less than 5 years of age. Geneva: World Health Organization; 2000. p. 34.
    1. Simoes EA, Carbonell-Estrany X, Rieger CH, Mitchell I, Fredrick L, Groothuis JR. The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children. J Allergy Clin Immunol. 2010;126(2):256–262. doi: 10.1016/j.jaci.2010.05.026. - DOI - PMC - PubMed
    1. Singleton RJ, Redding GJ, Lewis TC, Martinez P, Bulkow L, Morray B, Peters H, Gove J, Jones C, Stamey D, Talkington DF, DeMain J, Bernert JT, Butler JC. Sequelae of Severe Respiratory Syncytial Virus Infection in Infancy and Early Childhood Among Alaska Native Children. Pediatrics. 2003;112:285–290. doi: 10.1542/peds.112.2.285. - DOI - PubMed

MeSH terms

Substances